Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982928 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL207023 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL8345 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL16212282 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5717505 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL24141674 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL7736439 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL12041986 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5982921 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL8409010 | 0.95 | DNMT1 (0.58) | DNMT1ADRB1ALBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | disclosed |
| WO-2010093435-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | DNMT1 111/4885ADRB1 2700/4885ALB 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.